

February 28, 2024

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Outcome of Board Meeting

In reference to our letter dated February 09, 2024, we wish to inform you that the Board of Directors at their meeting held today i.e., February 28, 2024, have *inter-alia*, approved the following:

1. Sub-Division/ Split of Equity Shares of the Company

Board of Directors considered and approved the proposal for sub-division/ split of Equity Shares of the Company, such that, 1 (One) Equity Share having face value of Rs. 10/- (Rupees Ten only) each be sub-divided into 5 (Five) equity shares having face value of Rs. 2/- (Rupees Two only) each, subject to regulatory/ statutory approvals as may be required and the approval of Shareholders of the Company.

Further, the Board of Directors recommended consequential amendment in the Capital Clause of the Memorandum of Association of the Company, subject to approval of the Shareholders of the Company. The record date for sub-division/ split of equity shares shall be decided by the Board and will be intimated to the exchange.

The detailed disclosure as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is provided in **Annexure A**.

The Board meeting commenced at 11:30 a.m. (IST) and concluded at 12:00 Noon (IST).

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

Udayan Shukla

(Company Secretary and Compliance Officer)

Membership No.: F11744

Encl.: as above

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Balaxi Pharmaceuticals Limited

Annexure – A

Details required under SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sub-Division/ Split of Equity Shares of the Company:

| Sno. | Particulars | Remarks | | | | | | |
|------|--|--|----------------------|---------------------|------------------------------|----------------------|---------------------|------------------------------|
| 1. | Split Ratio | 1:5 i.e., existing 1 (one) equity share having face value of Rs. 10/- (Rupees Ten only) each, into 5 (five) equity shares having face value of Rs. 2/- (Rupees Two only) each. | | | | | | |
| 2. | Rationale behind the split | To enhance the liquidity in the capital market, to widen shareholder base and to make the shares more affordable to small investors. | | | | | | |
| 3. | Pre and post share capital – authorized, paid-up and subscribed | Types of Capital | Pre-Sub-Division | | | Post Sub-Division | | |
| | | | No. of Equity Shares | Face Value (In Rs.) | Total Share Capital (In Rs.) | No. of Equity Shares | Face Value (In Rs.) | Total Share Capital (In Rs.) |
| | | Authorised Share Capital | 4,00,00,000 | 10/- | 40,00,00,000/- | 20,00,00,000 | 2/- | 40,00,00,000/- |
| | | Issued, Subscribed and Paid-Up Share Capital | 1,07,47,250 | 10/- | 10,74,72,500/- | 5,37,36,250 | 2/- | 10,74,72,500/- |
| 4. | Expected time of completion | Within 2 months from the date of shareholder's approval. | | | | | | |
| 5. | Class of shares which are sub-divided | Equity Shares | | | | | | |
| 6. | Number of shares of each class pre and post split | Same as in Point No. 3 above Company has issued only one class of Equity Shares | | | | | | |
| 7. | Number of shareholders who did not get any shares in consolidation and their pre-consolidation shareholding. | Not Applicable | | | | | | |

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in